Spotlight on Hematology/Oncology
Helping Patients Overcome Enrollment Barriers in Blood Cancer Trials
By Scott Kerwin, MN, RN, CCRC, CCRN
The goal of increasing clinical trial enrollment in cancer trials has been around for many years, yet there has been little success. Patient and system barriers have been widely studied, yet fewer than 10 percent of cancer patients participate in clinical trials, and less than 20 percent of patients say their physician discussed clinical trials with them.
EARN CME CREDIT NOW!
By Brandon May
Primarily due to its high prevalence and the ease of access to suitable study material, chronic lymphocytic leukemia is at the forefront of genomics and human tumor research. Earn CME credit now!
HIGHLIGHTS IN HEMATOLOGY COLUMN
By Naveen Pemmaraju, MD
It is, in the end, in between the clinic visits in which real life takes place, and where the full story of the patient's existence, their livelihood, their humanity is truly residing, and we must strive to know more about this life “outside of the clinic” as this is indeed a person's real-life story unfolding, waiting to be heard. Let the silence in the clinic be that portal into our patient's life out of the clinic, their life “in between visits.” Click here to read more from Dr. Pemmaraju!
By Heidi D. Finnes, PharmD, BCOP
Acalabrutinib is approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior treatment.
Looking for disease-specific hematology content? Subscribe to a collection and never miss the latest research and treatment updates:
FEATURED YOUNG INVESTIGATOR
By Valerie Neff Newitt
Eirini Papapetrou, MD, PhD, Associate Professor at Icahn School of Medicine at Mount Sinai, New
York, N.Y., has emerged as one of the first investigators to produce induced pluripotent stem (iPS) cells that allow an extraordinary opportunity for deepening research.